- H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating.
- The Company announced “exceptionally strong” data that showed Lytenava’s statistically significant superiority over Lucentis, analyst Douglas Tsao tells investors in a research note.
- he sees the 18% difference in the response rate as “leaving no doubt about Lytenava’s performance.” Tsao raised the drug’s probability of success in wet macular degeneration to 80%.
- Early Tuesday, Lytenava aced the late-stage trial with a proportion of patients who gain at least 15 letters in the best-corrected visual acuity at 11 months.
- Price Action: OTLK shares are up 8.19% at $2.45 during the market session on the last check Tuesday.
HC Wainwright Raises Price Target On Outlook Therapeutics After Wet AMD Trial Data
H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company…